New drug combo aims to overcome resistance in lung cancer treatment
Disease control
Completed
This early-phase trial tested whether adding copanlisib to the standard immune therapy durvalumab is safe for people with stage III non-small cell lung cancer that cannot be removed by surgery. The study enrolled 11 participants who had already received chemotherapy and radiation…
Phase: PHASE1 • Sponsor: Zhonglin Hao • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC